The trial focuses on patients with relapsed/refractory AML, especially those with specific mutations like FLT3 , U2AF1 , or SF3B1 , which are known to drive IRAK4 activity. Pharmaceutical Manufacturing & Development
The drug has received clearance from both the FDA (United States) and the NMPA (China) to begin Phase 1 clinical trials. KBI-092
This open-label study is designed to assess the safety, tolerability, and pharmacokinetics of the drug. It typically begins with a dose of 30 mg twice daily (BID), escalating up to 200 mg BID to determine the Recommended Phase 2 Dose (RP2D). The trial focuses on patients with relapsed/refractory AML,
This protein is a central mediator in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. These pathways are frequently hijacked by cancer cells to promote inflammation and evade cell death, particularly in patients who have failed prior FLT3 inhibitor therapy. It typically begins with a dose of 30
Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins: